tbuckley/cabot-search huggingface dataset:
Genome-wide association analyses highlight etiological differences underlying newly defined subtypes of diabetes
Authors: Dina Mansour Aly, Om Prakash Dwivedi, Rashmi B. Prasad, Annemari Käräjämäki, Rebecka Hjort, Manonanthini Thangam, Mikael Åkerlund, Anubha Mahajan, Miriam S. Udler, Jose C. Florez, Mark I. McCarthy, Goncalo Abecasis, Aris Baras, Michael Cantor, Giovanni Coppola, Aris Economides, Luca A. Lotta, John D. Overton, Jeffrey G. Reid, Alan Shuldiner, Christina Beechert, Caitlin Forsythe, Erin D. Fuller, Zhenhua Gu, Michael Lattari, Alexander Lopez, Thomas D. Schleicher, Maria Sotiropoulos Padilla, Louis Widom, Sarah E. Wolf, Manasi Pradhan, Kia Manoochehri, Ricardo H. Ulloa, Xiaodong Bai, Suganthi Balasubramanian, Andrew Blumenfeld, Gisu Eom, Lukas Habegger, Alicia Hawes, Shareef Khalid, Evan K. Maxwell, William Salerno, Jeffrey C. Staples, Marcus B. Jones, Lyndon J. Mitnaul, Julia Brosnan, Olle Melander, Sofia Carlsson, Ola Hansson, Tiinamaija Tuomi, Leif Groop, Emma Ahlqvist
Journal: Nature Genetics (2021)
Trends in Mortality Among Pregnant and Recently Pregnant Women in the US, 2015-2019
Authors: Jeffrey T. Howard, Corey S. Sparks, Alexis R. Santos-Lozada, Samson A. Olowolaju, Jud C. Janak, Krista J. Howard
Journal: JAMA (2021)

some vaccines may have been missed, potentially biasing findings to the null.Third, data on important confounders, such as prior pregnancy history, were not available.Fourth, it was not possible to assess risks specific to the Ad26.COV.
Global Longitudinal Strain and Left Atrial Volume Index Provide Incremental Prognostic Value in Patients With Hypertrophic Cardiomyopathy
Authors: Y.L. Hiemstra, P. Debonnaire, M. Bootsma, E.W. van Zwet, V. Delgado, M.J. Schalij, D.E. Atsma, J.J. Bax, N.A. Marsan
Journal: Circulation (2017)
Regional Variation in Surgical Procedure Rates
Authors: Michael M. Ward
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
TCT-420 Sex Differences in Age-Stratified Outcomes After Transcatheter Aortic Valve Replacement: Insights From the National Inpatient Sample 2012 to 2018
Authors: Salman Zahid, Muhammad Khan, Waqas Ullah, Devesh Rai, Mian Tanveer Ud Din, Sakina Abbas, Aamer Ubaid, Muhammad Khan, Fnu Salman, Sammarthkumar Thakkar, Amr Salama, Sudarshan Balla, Mohamad Alkhouli, Jeremiah Depta, Erin Michos
Journal: Journal of the American College of Cardiology (2021)
Diffusion-Weighted Magnetic Resonance Imaging in the Evaluation of Wilms Tumors: Correlation with Histological Data. Pilot Study
Authors: E. E. Manzhurtsevа, V. A. Lopatina, P. Ye. Men’shchikov, G. V. Tereshchenko
Journal: Radiology - Practice (2021)

The aim of the study is to assess the difference in apparent diffusion coefficient (ADC) values depending on the degrees of malignancy of Wilms’ tumor. The study includes 64 patients with verified Wilms tumor after a course of chemotherapy, before undergoing surgical treatment. The patients were examined using scanners with magnetic field induction of 3.0 and 1,5 T. ADC data collection (mm2/s) was carried out using specialized software. Statistical analysis was performed using the Graphpad Prism software package. Based on the results of this study, average ADC values were obtained for histological types of Wilms’ tumors distributed by clinical risk groups: 0.4 × 10 -3 mm 2 /s — for the low grade of malignancy, 1.1 × 10 -3 mm 2 /s — for the average grade of malignancy and 0.6 × 10-3 mm2/s — for the high grade. In addition, for the average grade of malignancy, the ADC values were divided into groups depending on the cellular composition — 1 ± 0.2 × 10 -3 mm 2 /s — for the regressive and mixed type; 0.9 ± 0.2 × 10 -3 mm 2 /s — for the epithelial type; 1.3 ± 0.4 × 10 -3 mm 2 /s — for the stromal type. Thus, diffusion-weighted MRI can be a useful tool in the initial assessment and differential diagnosis of patients with Wilms tumor.
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment
Authors: Raymond S. Douglas, George J. Kahaly, Shoaib Ugradar, Heike Elflein, Katharina A. Ponto, Brian T. Fowler, Roger Dailey, Gerald J. Harris, Jade Schiffman, Rosa Tang, Sara Wester, Amy Patel Jain, Claudio Marcocci, Michele Marinò, Alessandro Antonelli, Anja Eckstein, Dagmar Führer-Sakel, Mario Salvi, Saba Sile, Megan Francis-Sedlak, Robert J. Holt, Terry J. Smith
Journal: Ophthalmology (2021)

To evaluate teprotumumab safety/efficacy in patients with thyroid eye disease (TED) who were nonresponsive or who experienced a disease flare.The Treatment of Graves' Orbitopathy to Reduce Proptosis with Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X) is a teprotumumab treatment and re-treatment trial following the placebo-controlled teprotumumab Phase 3 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis with Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC) trial.Patients who previously received placebo (n = 37) or teprotumumab (n = 14) in OPTIC.OPTIC nonresponders or those who flared (≥2-mm increase in proptosis, ≥2-point increase in clinical activity score [CAS], or both) during follow-up were treated for the first time (previous placebo patients) or re-treated with teprotumumab in OPTIC-X with 8 infusions over 24 weeks.Proptosis response and safety. Secondary outcomes included proptosis, CAS, subjective diplopia, and quality-of-life.Thirty-three of 37 placebo-treated OPTIC patients (89.2%) became proptosis responders (mean ± standard deviation, -3.5 ± 1.7 mm) when treated with teprotumumab in OPTIC-X. The responses were equivalent to the OPTIC study. In these responders, proptosis, CAS of 0 or 1, and diplopia responses were maintained in 29 of 32 patients (90.6%), 20 of 21 patients (95.2%), and 12 of 14 patients (85.7%), respectively, at follow-up week 48. The median TED duration was 12.9 months versus 6.3 months in those treated with teprotumumab in the OPTIC study. Of the 5 OPTIC teprotumumab nonresponders re-treated in OPTIC-X, 2 responded, 1 showed a proptosis reduction of 1.5 mm from OPTIC baseline, and 2 discontinued treatment early. Of the OPTIC teprotumumab responders who experienced flare, 5 of 8 patients (62.5%) responded when re-treated (mean proptosis reduction, 1.9 ± 1.2 mm from OPTIC-X baseline and 3.3 ± 0.7 mm from OPTIC baseline). Compared with published double-masked trials and their integrated follow-up, no new safety signals were identified. Mild hearing impairment was reported; 4 events occurred during the first course of treatment, and 2 events reoccurred after re-treatment.Patients with TED of longer disease duration responded similarly to those treated earlier in the disease course. Patients with an insufficient initial response or flare may benefit from additional teprotumumab therapy. No new safety risk was identified; however additional postmarketing pharmacovigilance is ongoing.
A polymer‑calcium phosphate nanocapsule for RNAi-induced oxidative stress and cascaded chemotherapy
Authors: Jinsheng Huang, Chujie Zheng, Hong Xiao, Huiling Huang, Yiyao Wang, Minzhao Lin, Jun Pang, Yong Wang, Yuanyuan Yuan, Xintao Shuai
Journal: Journal of Controlled Release (2021)
Constant V<scp>t</scp> Ventilation and Surfactant Dysfunction: An Overlooked Cause of Ventilator-induced Lung Injury
Authors: Richard K. Albert
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

Ventilator-induced lung injury (VILI) is currently ascribed to volutrauma and/or atelectrauma, but the effect of constant Vt ventilation (CVtV) has received little attention. This Perspective summarizes the literature documenting that CVtV causes VILI and reviews the mechanisms by which it occurs. Surfactant is continuously inactivated, depleted, displaced, or desorbed as a function of the duration of ventilation, the Vt, the level of positive end-expiratory pressure (PEEP), and possibly the respiratory rate. Accordingly, surfactant must be continuously replenished, and secretion primarily depends on intermittent delivery of large ventilatory excursions. The surfactant abnormalities resulting from CVtV result in atelectasis and VILI. Although surfactant secretion is reduced by the absence of intermittent deep breaths, continuous administration of large Vts depletes surfactant and impairs subsequent secretion. Low or normal lung volumes result in desorption of surfactant. PEEP can be protective by reducing surface film collapse and subsequent film rupture on reexpansion, and/or by reducing surfactant displacement into the airways, but PEEP can also downregulate surfactant release. The effect of CVtV on surfactant is complex. If attention is not paid to facilitating surfactant secretion and limiting its inactivation, depletion, desorption, or displacement, surface tension will increase and atelectasis and VILI will occur.
MicroRNA profiles and potential capacities as biomarker in human endometrioid adenocarcinoma
Authors: Choi, CH[Choi, Chel Hun], Choi, JJ[Choi, Jung-Joo], Park, YA[Park, Young Ae], Kim, TJ[Kim, Tae-Joong], Lee, JW[Lee, Jeong-Won], Kim, CJ[Kim, Chul Joong], Lee, YY[Lee, You-Young], Kim, BG[Kim, Byoung-Gie], Lee, JH[Lee, Je-Ho], Bae, DS[Bae, Duk-Soo], Lee, EJ[Lee, Eun-Ju]
Journal: Cancer Research (2009)
Mapping conflict of interests: scoping review
Authors: Susan Chimonas, Maha Mamoor, Sophia A Zimbalist, Brooke Barrow, Peter B Bach, Deborah Korenstein
Journal: BMJ (2021)

Abstract Objective To identify all known ties between the medical product industry and the healthcare ecosystem. Design Scoping review. Methods From initial literature searches and expert input, a map was created to show the network of medical product industry ties across parties and activities in the healthcare ecosystem. Through a scoping review, the ties were then verified, cataloged, and characterized, with data abstracted on types of industry ties (financial, non-financial), applicable policies for conflict of interests, and publicly available data sources. Main outcome measures Presence and types of medical product industry ties to activities and parties, presence of policies for conflict of interests, and publicly available data. Results A map derived through synthesis of 538 articles from 37 countries shows an extensive network of medical product industry ties to activities and parties in the healthcare ecosystem. Key activities include research, healthcare education, guideline development, formulary selection, and clinical care. Parties include non-profit entities, the healthcare profession, the market supply chain, and government. The medical product industry has direct ties to all parties and some activities through multiple pathways; direct ties extend through interrelationships among parties and activities. The most frequently identified parties were within the healthcare profession, with individual professionals described in 422 (78%) of the included studies. More than half (303, 56%) of the publications documented medical product industry ties to research, with clinical care (156, 29%), health professional education (145, 27%), guideline development (33, 6%), and formulary selection (8, 1%) appearing less often. Policies for conflict of interests exist for some financial and a few non-financial ties; publicly available data sources seldom describe or quantify these ties. Conclusions An extensive network of medical product industry ties to activities and parties exists in the healthcare ecosystem. Policies for conflict of interests and publicly available data are lacking, suggesting that enhanced oversight and transparency are needed to protect patient care from commercial influence and to ensure public trust.
染色体にコードされた誘導性AmpC β-ラクタマーゼによる腸内細菌目におけるセフェピムMICに対するAmpC脱抑制の影響【JST・京大機械翻訳】
Authors: R Kohlmann, T Baehr, S G Gatermann
Journal: Clinical Microbiology and Infection (2019)
The histone lysine acetyltransferase HBO1 (KAT7) regulates hematopoietic stem cell quiescence and self-renewal
Authors: Yuqing Yang, Andrew J. Kueh, Zoe L. Grant, Waruni Abeysekera, Alexandra L. Garnham, Stephen Wilcox, Craig D. Hyland, Ladina Di Rago, Don Metcalf, Warren S. Alexander, Leigh Coultas, Gordon K. Smyth, Anne K. Voss, Tim Thomas
Journal: Blood (2021)
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization
Authors: Connie N. Hess, Manesh R. Patel, Rupert M. Bauersachs, Sonia S. Anand, E. Sebastian Debus, Mark R. Nehler, Fabrizio Fanelli, Robert W. Yeh, Eric A. Secemsky, Joshua A. Beckman, Laura Mauri, Nicholas Govsyeyev, Warren H. Capell, Taylor Brackin, Scott D. Berkowitz, Eva Muehlhofer, Lloyd P. Haskell, William R. Hiatt, Marc P. Bonaca
Journal: Journal of the American College of Cardiology (2021)

Paclitaxel drug-coated devices (DCDs) were developed to improve lower extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been associated with long-term mortality.
Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients
Authors: Pauline P. Chen, Alma-Martina Cepika, Rajni Agarwal-Hashmi, Gopin Saini, Molly J. Uyeda, David M. Louis, Brandon Cieniewicz, Mansi Narula, Laura C. Amaya Hernandez, Nicholas Harre, Liwen Xu, Benjamin Craig Thomas, Xuhuai Ji, Parveen Shiraz, Keri M. Tate, Dana Margittai, Neehar Bhatia, Everett Meyer, Alice Bertaina, Mark M. Davis, Rosa Bacchetta, Maria Grazia Roncarolo
Journal: Science Translational Medicine (2021)

Type 1 regulatory T cells suppress alloreactive immune cells after adoptive transfer in a CTLA-4 and PD-1–mediated manner.
Abstract 2824: Drug Eluting Stents Implantation In Acute Myocardial Infarction Significantly Delays Healing And Increases Stent Thrombosis
Authors: Gaku Nakazawa, Michael Joner, Elena Ladich, Aloke V Finn, Erik K Mont, Robert Kutys, Allen Burke, Frank D Kolodgie, Renu Virmani
Journal: Circulation (2007)

Background Although early clinical results of DES implantation for acute myocardial infarction (AMI) show no significant differences in late thrombosis however, long-term safety is still unclear. We evaluated the pathologic responses following DES implantation in AMI patients and compared to stents implanted in non-AMI lesions. Methods From CVPath DES autopsy registry of 116 cases, we identified 22 who presented with AMI at the time of DES implantation and had underlying plaque rupture (PR) or thin-cap fibroatheroma (TCFA). Morphometric analysis was performed using calibrated software (IPLab, Scanalytics) in patients who died ≥30 days after DES implantation. The percentage of struts with fibrin deposition, inflammation (&gt;10 cells/strut), and uncovered struts were also recorded. We assessed arterial healing, by comparing culprit to non-culprit sites within each stented section. Furthermore, age and stent duration matched non-AMI patients who had underlying fibroatheroma (FA) lesion were selected as controls. Results Of the 22 patients with AMI, 14 died ≥30 days (mean duration: 285±277 days) and stent thrombosis was documented in 7 (50%, mean duration: 333±396 days), whereas in non-AMI patients with underlying FA, thrombosis was significantly less frequent (8%). Morphometric analysis revealed neointimal thickness was significantly less in culprit sites as compared to non-culprit sites in AMI patients. The percentages of uncovered struts, and struts with inflammation were significantly greater in culprit sites as compared to non-culprit sites in AMI lesions. Lesions in non-AMI patients were significantly different from AMI patients with greater neointimal thickness, less fibrin around struts, inflammation and uncovered struts (Table ). Conclusions A higher prevalence of stent thrombosis was observed in patients with AMI than those without AMI and is associated with substantial delayed in arterial healing especially at culprit sites. Pathologic and Morphmetric Analysis, Culprit vs. Non-Culprit and AMI vs. Non-AMI
Identification and drug-induced reversion of molecular signatures of Alzheimer’s disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models
Authors: Eduardo Pauls, Sergi Bayod, Lídia Mateo, Víctor Alcalde, Teresa Juan-Blanco, Marta Sánchez-Soto, Takaomi C. Saido, Takashi Saito, Antoni Berrenguer-Llergo, Camille Stephan-Otto Attolini, Marina Gay, Eliandre de Oliveira, Miquel Duran-Frigola, Patrick Aloy
Journal: Genome Medicine (2021)

Abstract Background In spite of many years of research, our understanding of the molecular bases of Alzheimer’s disease (AD) is still incomplete, and the medical treatments available mainly target the disease symptoms and are hardly effective. Indeed, the modulation of a single target (e.g., β-secretase) has proven to be insufficient to significantly alter the physiopathology of the disease, and we should therefore move from gene-centric to systemic therapeutic strategies, where AD-related changes are modulated globally. Methods Here we present the complete characterization of three murine models of AD at different stages of the disease (i.e., onset, progression and advanced). We combined the cognitive assessment of these mice with histological analyses and full transcriptional and protein quantification profiling of the hippocampus. Additionally, we derived specific Aβ-related molecular AD signatures and looked for drugs able to globally revert them. Results We found that AD models show accelerated aging and that factors specifically associated with Aβ pathology are involved. We discovered a few proteins whose abundance increases with AD progression, while the corresponding transcript levels remain stable, and showed that at least two of them (i.e., lfit3 and Syt11) co-localize with Aβ plaques in the brain. Finally, we found two NSAIDs (dexketoprofen and etodolac) and two anti-hypertensives (penbutolol and bendroflumethiazide) that overturn the cognitive impairment in AD mice while reducing Aβ plaques in the hippocampus and partially restoring the physiological levels of AD signature genes to wild-type levels. Conclusions The characterization of three AD mouse models at different disease stages provides an unprecedented view of AD pathology and how this differs from physiological aging. Moreover, our computational strategy to chemically revert AD signatures has shown that NSAID and anti-hypertensive drugs may still have an opportunity as anti-AD agents, challenging previous reports.
TCT-48 Incidence and Outcomes of Atrial Fibrillation in Patients Undergoing TAVR Versus SAVR: Experience From SURTAVI and Low-Risk Randomized Studies
Authors: Amit Vora, Hemal Gada, Matthew Sherwood, Renato Lopes, John Forrest, Jian Huang, Michael Reardon
Journal: Journal of the American College of Cardiology (2021)
HLA alleles associated with asparaginase hypersensitivity in Chinese children
Authors: Gilbert T. Chua, Jaime S. Rosa Duque, Daniel Ka Leung Cheuk, Alex Wing Kwan Leung, Wilfred Hing Sang Wong, Anthony Pak Yin Liu, Pamela P. W. Lee, Shau Yin Ha, Alan Kwok Shing Chiang, Marco Hok Kung Ho, Wai Keung Chu, Yuk Sing Chan, Chun Wing Luk, Alvin Siu Cheung Ling, Mike Yat Wah Kwan, Oscar Kuen Fong Yiu, Ian Chi Kei Wong, Yu Lung Lau, Chi Kong Li, Wing Hang Leung, Godfrey Chi Fung Chan, Patrick Ip, Janette Kwok
Journal: Journal of Hematology & Oncology (2021)

Asparaginase is an important drug to treat childhood haematological malignancies. Data on the association between human leukocyte antigens (HLA) and asparaginase hypersensitivity among Chinese are lacking. We conducted a retrospective study to identify HLA alleles associated with asparaginase hypersensitivity among Chinese children with acute lymphoblastic leukaemia (ALL), mixed phenotype leukaemia and non-Hodgkin lymphoma (NHL), who received asparaginases with HLA typing performed between 2009 and 2019. 107 Chinese patients were analysed. 66.3% (71/107) developed hypersensitivity to at least one of the asparaginases. HLA-B*46:01 (OR 3.8, 95% CI 1.4-10.1, p < 0.01) and DRB1*09:01 (OR 4.3, 95% CI 1.6-11.4, p < 0.01) were significantly associated with L-asparaginase hypersensitivities, which remained significant after adjustment for age, gender and B cell ALL [HLA-B*46:01 (adjusted OR 3.5, 95% 1.3-10.5, p = 0.02) and DRB1*09:01 (OR 4.4, 95% CI 1.6-13.3, p < 0.01)].
Cell-Type-Specific Impact of Glucocorticoid Receptor Activation on the Developing Brain: A Cerebral Organoid Study
Authors: Cristiana Cruceanu, Leander Dony, Anthi C. Krontira, David S. Fischer, Simone Roeh, Rossella Di Giaimo, Christina Kyrousi, Lea Kaspar, Janine Arloth, Darina Czamara, Nathalie Gerstner, Silvia Martinelli, Stefanie Wehner, Michael S. Breen, Maik Koedel, Susann Sauer, Vincenza Sportelli, Monika Rex-Haffner, Silvia Cappello, Fabian J. Theis, Elisabeth B. Binder
Journal: American Journal of Psychiatry (2021)

A fine-tuned balance of glucocorticoid receptor (GR) activation is essential for organ formation, with disturbances influencing many health outcomes. In utero, glucocorticoids have been linked to brain-related negative outcomes, with unclear underlying mechanisms, especially regarding cell-type-specific effects. An in vitro model of fetal human brain development, induced human pluripotent stem cell (hiPSC)-derived cerebral organoids, was used to test whether cerebral organoids are suitable for studying the impact of prenatal glucocorticoid exposure on the developing brain.The GR was activated with the synthetic glucocorticoid dexamethasone, and the effects were mapped using single-cell transcriptomics across development.The GR was expressed in all cell types, with increasing expression levels through development. Not only did its activation elicit translocation to the nucleus and the expected effects on known GR-regulated pathways, but also neurons and progenitor cells showed targeted regulation of differentiation- and maturation-related transcripts. Uniquely in neurons, differentially expressed transcripts were significantly enriched for genes associated with behavior-related phenotypes and disorders. This human neuronal glucocorticoid response profile was validated across organoids from three independent hiPSC lines reprogrammed from different source tissues from both male and female donors.These findings suggest that excessive glucocorticoid exposure could interfere with neuronal maturation in utero, leading to increased disease susceptibility through neurodevelopmental processes at the interface of genetic susceptibility and environmental exposure. Cerebral organoids are a valuable translational resource for exploring the effects of glucocorticoids on early human brain development.
Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection
Authors: Diana Zhong, Shaoming Xiao, Amanda K. Debes, Emily R. Egbert, Patrizio Caturegli, Elizabeth Colantuoni, Aaron M. Milstone
Journal: JAMA (2021)

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar